


Additional studies identified since previous reviews: N = 4 citations relating to 5 studies:

- Pegfilgrastim vs. no primary G-CSF: 4 additional RCTs (within 3 citations)
- Filgrastim vs. no primary G-CSF: 1 additional RCT (1 citation)



Total full papers included, from updated search and previous reviews: N = 23 citations relating to 25 studies:

- Pegfilgrastim vs. no primary G-CSF: 5 RCTs (within 4 citations)
- Filgrastim vs. no primary G-CSF: 10 RCTs (within 9 citations)
- Lenograstim vs. no primary G-CSF: 5 RCTs
- Pegfilgrastim vs. filgrastim: 5 RCTs
- Pegfilgrastim vs. lenograstim: 0 RCTs
- Lenograstim vs. filgrastim: 0 RCTs